Li Wei, Long Jian-Dong, Qian Yuan-Yuan, Long Yu, Xu Xue-Jun, Wang Yu-Jun, Shen Qing, Wang Zuo-Neng, Yang Xi-Cheng, Xiao Li, Sun Hong-Peng, Xu Yu-Long, Chen Yi-Yi, Xie Qiong, Wang Yong-Hui, Shao Li-Ming, Liu Jing-Gen, Qiu Zhui-Bai, Fu Wei
Department of Medicinal Chemistry, School of Pharmacy, Fudan University , Shanghai 201203, China.
Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Collaborative Innovation Center for Brain Science , Shanghai 201203, China.
ACS Chem Neurosci. 2017 Apr 19;8(4):766-776. doi: 10.1021/acschemneuro.6b00321. Epub 2017 Jan 19.
To develop novel analgesics with no side effects or less side effects than traditional opioids is highly demanded to treat opioid receptor mediated pain and addiction issues. Recently, κ-opioid receptor (KOR) has been established as an attractive target, although its selective agonists could bear heterogeneous pharmacological activities. In this study, we designed and synthesized two new series of nepenthone derivatives by inserting a spacer (carbonyl) between 6α,14α-endo-ethenylthebaine and the 7α-phenyl substitution of the skeleton and by substituting the 17-N-methyl group with a cyclopropylmethyl group. We performed in vitro tests (binding and functional assays) and molecular docking operations on our newly designed compounds. The results of wet-experimental measures and modeled binding structures demonstrate that these new compounds are selective KOR agonists with nanomolar level affinities. Compound 4 from these new derivatives showed the highest affinity (K = 0.4 ± 0.1 nM) and the highest selectivity (μ/κ = 339, δ/κ = 2034) toward KOR. The in vivo tests revealed that compound 4 is able to induce stronger (ED = 2.1 mg/kg) and much longer antinociceptive effect than that of the typical KOR agonist U50488H (ED = 4.4 mg/kg). Therefore, compound 4 can be used as a perfect lead compound for future design of potent analgesics acting through KOR.
开发新型镇痛药,使其没有副作用或比传统阿片类药物副作用更少,对于治疗阿片受体介导的疼痛和成瘾问题至关重要。最近,κ-阿片受体(KOR)已成为一个有吸引力的靶点,尽管其选择性激动剂可能具有多种药理活性。在本研究中,我们通过在6α,14α-内乙烯基蒂巴因与骨架的7α-苯基取代基之间插入一个间隔基(羰基),并将17-N-甲基用环丙基甲基取代,设计并合成了两个新系列的马兜铃酮衍生物。我们对新设计的化合物进行了体外测试(结合和功能测定)以及分子对接操作。湿实验测量结果和模拟结合结构表明,这些新化合物是具有纳摩尔水平亲和力的选择性KOR激动剂。这些新衍生物中的化合物4对KOR表现出最高的亲和力(K = 0.4 ± 0.1 nM)和最高的选择性(μ/κ = 339,δ/κ = 2034)。体内测试表明,化合物4能够诱导出比典型KOR激动剂U50488H更强(ED = 2.1 mg/kg)且持续时间更长的镇痛作用(ED = 4.4 mg/kg)。因此,化合物4可作为未来设计通过KOR起作用的强效镇痛药的理想先导化合物。